Oncothyreon (ONTY) Misses Q4 EPS by 21c

Oncothyreon (NASDAQ: ONTY) reported Q4 EPS of ($0.30), $0.21 worse than the analyst estimate of ($0.09).

As of December 31, 2014, Oncothyreon's cash, cash equivalents and investments were $63.7 million, compared to $72.6 million at December 31, 2013, a decrease of $8.9 million, or 12.3 percent. The decrease was primarily attributable to $48.4 million of cash used in operations during the year ended December 31, 2014, partially offset by the net proceeds of $40.2 million from the closing of concurrent but separate underwritten offerings of Oncothyreon common stock and Series A convertible preferred stock in September 2014.

For earnings history and earnings-related data on Oncothyreon (ONTY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c